As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...
Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has initiated a Phase 3 study titled ‘A ...
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...
CINCINNATI, Ohio. (Ivanhoe Newswire) --- Schizophrenia - the statistics are terrifying; more than 3.7 million people are living with it right now in the United States. If left untreated it can be ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares began Tuesday sharply higher. The company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...
Schizophrenia is a mental health disorder that causes changes to the way a person thinks, acts, and behaves. People with schizophrenia may have hallucinations, delusions, disorganized behavior, and ...
Verywell Health on MSN
What is undifferentiated schizophrenia?
While undifferentiated schizophrenia is no longer listed in the American Psychiatric Association's Diagnostic and Statistical ...
A special research fund of 50,000 pounds sterling ($140,000) for studies to promote better understanding, prevention, treatment and cure of schizophrenia was established on behalf of the Rothschild ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback